Note to researchers and pharmaceutical companies – Both models of ARSACS transgenic mice now available at the Jackson Laboratory.
Both ARSACS transgenic mouse models, the Sacs Knock Out mouse (# 033221) and the Sacs Knock In R272C mouse (# 033385), are now available for sell on the Jackson Laboratory website www.jax.org.
Thanks to the financial support of the Ataxia Charlevoix-Saguenay Foundation, the mice generated and characterized by the ARSACS researcher team demonstrate similarities to the disease found in humans (Larivière et al., 2015 and Larivière et al., 2019).
For any questions, please contact the Ataxia Charlevoix-Saguenay Foundation at the following email address: email@example.com
Over the years, a greater collaboration has developed among ARSACS researchers. See a representation of the network of collaboration produced by Mathieu Blais.
As part of its going research program, the Foundation is pleased to announce that it will fund 12 research projects in 2019-2020. Details to come .
The Ataxia Charlevoix-Saguenay Foundation cordially invites you to its annual fundraising Le Diner des Producteurs (13th edition)
under the honorary presidency of Mr. Jacques Foisy, Chairman of the Board and Managing Partner, Novacap. Invitation.
On June 11th, thanks to Manon Valiquette, Sonia Gobeil representing the Foundation had the pleasure of visiting the Institute for Research in Immunology and Cancer (IRCI) in Montreal and discovering extraordinary people who are very passionate about their work. Their ARSACS project consists in optimizing active molecules aimed at producing a reversal of the ARSACS phenotype in an In Vivo model. Thank you very much for your time. For more information.
The acronym “ARSACS” enters the life of Susanna de Luca and Paolo Arrigoni when their young child was diagnosed with ARSACS. Paolo joined the Board of Directors of the Ataxia Charlevoix-Saguenay Foundation in 2018 and, after having participated in the international symposium on ARSACS in Montreal, concluded that a point of reference and support was necessary in Europe, especially since several cases have been identified.
In December 2018, these parents created the ARSACS Organizzazione Di Volontariato (ARSACS ODV) based in Milan, Italy. Like the Ataxia Charlevoix-Saguenay Foundation, it is an organisation of volunteers, with a legal status, working in close collaboration with the Foundation. ARSACS ODV wishes to increase the awareness of ARSACS in Europe, to be a point of reference and support and to help finance the research projects via the Foundation.
Dr. Brais will be presenting “New insights on ARSACS lead to a search for candidate compounds“ at the 6th International Meeting on Spastic Paraparesis and Ataxia on September 20-21 2019 in Nice, France. The program includes plenary talks from leaders in the field of spinocerebellar diseases (dominant and recessive forms of cerebellar ataxias and spastic paraplegias)
On April 25th in Quebec City, Sonia Gobeil had the pleasure of meeting Dr. Esther Becker (Oxford University) and attending her conference on the cerebellum entitled “New Insights into Cerebellar Disorders”. Summary.
Dr. Cynthia Gagnon, member of the ARSACS research team, at the International Ataxia Research Conference
Dr. Cynthia Gagnon will be presenting on the Natural History, Biomarkers and Endpoints for ARSACS at the November 2019 International Ataxia Research Conference in Washington, DC
“Speech treatment improves dysarthria in multisystemic ataxia:
a raterblinded, controlled pilot-study in ARSACS” research study done by Dr. Synofzik and his research team to be published in the Journal of Neurology. To learn more about the study, interested readers can contact Dr. Matthis Synofzik directly. See Abstract
Article will be published in the Journal of the Neurological Sciences in May, 2019. The study concludes that adults with ARSACS may experience many other clinical manifestations than the most commonly described. See Article.
EMG data of 6 muscles from 35 ARSACS patients were obtained as part of Dr. Luc J. Hébert’s ARSACS research project. The analysis of these EMG data will help to better understand the problem of spasticity in ARSACS patients and could eventually open the door to new interventions targeted more on these neuro- locomotive deficiences.
The University of North Carolina (UNC) Catalyst for Rare Diseases, funded in 2016, was established as a precompetitive open research group with a mission to understand the functional phenotic manifestations of genetic mutations. This article describes the initial experiences and learning from the UNC Catalyst for Rare diseases.
Invitation to join us at the 13th edition of the Diner des Producteurs, major annual fundraising event for the Ataxia Charlevoix-Saguenay Foundation. Discover the fine cuisine prepared by guest chef Pierre Gagnaire 3 Michelin stars, wines from La Maison E. Guigal. You do not want to miss this great opportunity so reserve your table now.
The next meeting of the Board of the Ataxia Charlevoix-Saguenay Foundation will be held in Montreal on Wednesday June 5,2019.
If you or a family member has received an ARSACS diagnostic, you are invited to register. It is easy and simple.
The registry is available in 4 languages English, French Spanish and in Italian. This is a way for you to support the cause.